Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
tamoxifen-resistant cells
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "tamoxifen-resistant cells" in MCE Product Catalog:
644
644 Cited Publications
Target:
Research Areas:
ML385 is a potent and selective Nrf2 inhibitor with an IC50 of 1.9 μM. ML385 directly binds to the Neh1 domain of NRF2, interferes with the binding of the MAFG-NRF2 protein complex to the antioxidant response element (ARE) DNA sequence, thereby blocking the expression of downstream target genes of NRF2. ML385 can be used in studies related to adult T-cell leukemia, breast cancer, myocardial ischemia/reperfusion injury, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma .
3
3 Cited Publications
Research Areas:
A1874 is an orally active BRD4 PROTAC degrader with a DC50 of 32 nM. A1874 degrades BRD4 via the ubiquitin-proteasome system by recruiting the MDM2 E3 ligase, while disrupting the MDM2-p53 interaction to stabilize p53 and upregulate p21, thereby inducing cell cycle arrest and apoptosis. A1874 exhibits selectivity for wild-type p53 cells and MDM2-amplified tumors, and it can be used in research on breast cancer, colorectal cancer, melanoma, lung cancer, lymphoma, myeloid leukemia, osteosarcoma, and glioblastoma .
CDK2/4/6-IN-2 is a selective CDK2/4/6 inhibitor with IC50 values <1 μM. CDK2/4/6-IN-2 inhibits cells proliferation and phosphorylation of retinoblastoma protein at Ser807/811 in breast cancer cells. CDK2/4/6-IN-2 can be used for the research of cancer, such as breast cancer .
Cat. No.: HY-174453
Target:
Research Areas:
PROTAC ERα Degrader-12 is a VHL-recruiting ERα PROTAC degrader with a DC50 of 1.02 μM in MCF-7 cells. PROTAC ERα Degrader-12 binds to ERα and recruits the VHL E3 ligase to form a ternary complex, promoting proteasomal degradation of both wild-type and mutant ERα, thereby inhibiting ER-mediated transcriptional activity and breast cancer cell proliferation. PROTAC ERα Degrader-12 can be used in the research of ERα-positive breast cancer .
Cat. No.: HY-155197
CAS No.: 2922929-63-1
Research Areas:
ER degrader 7 is an estrogen receptor α (ERα) degrader and a tubulin (tubulin) inhibitor. ER degrader 7 inhibits the cell viability of various cancer cell lines. ER degrader 7 disrupts the microtubule network in breast cancer cells, induces G2/M phase cell cycle arrest, and exhibits concentration-dependent accumulation in Tamoxifen-resistant LCC2 cells. ER degrader 7 suppresses tumor growth in vivo without causing body weight loss. ER degrader 7 can be applied in studies related to breast cancer .
Cat. No.: HY-125675
CAS No.: 2027540-49-2
Target:
Research Areas:
VPC-16606 is a selective inhibitor targeting the activation function 2 (AF2) domain of estrogen receptor α (ERα). VPC-16606 blocks the interaction between ERα and coactivators, inhibits the activity of both wild-type and clinically drug-resistant mutant ERα, and exerts inhibitory effects on hormone-resistant breast cancer cells. VPC-16606 can be used in breast cancer research .
Cat. No.: HY-100523R
CAS No.: 846557-71-9
ML385 (Standard) is the analytical standard of ML385 (HY-100523). This product is intended for research and analytical applications. ML385 is a potent and selective Nrf2 inhibitor with an IC50 of 1.9 μM. ML385 directly binds to the Neh1 domain of NRF2, interferes with the binding of the MAFG-NRF2 protein complex to the antioxidant response element (ARE) DNA sequence, thereby blocking the expression of downstream target genes of NRF2. ML385 can be used in studies related to adult T-cell leukemia, breast cancer, myocardial ischemia/reperfusion injury, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
